New Programs, Product Launches, Corporate Announcements and Financial Results - Research Report on Aetna, Illumina, Pharmacyclics, WellCare, and BioCryst

NEW YORK, August 27, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Aetna Inc. (NYSE: AET), Illumina Inc. (NASDAQ: ILMN), Pharmacyclics Inc. (NASDAQ: PCYC), WellCare Health Plans, Inc. (NYSE: WCG), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Aetna Inc. Research Report

On August 20, 2013, Aetna Inc. (Aetna) announced a new pilot program called the Aetna Rx Home Success Program^SM. According to the Company, the program works in association with CVS Caremark pharmacists and Dovetail Health to support Aetna members who are taking multiple medications to manage their health through personal support from a pharmacist. The Company stated that under the new program, a pharmacist contacts enrolled members and work with them to schedule an in-home visit or a detailed phone consultation, review any new and/or pre-existing medications, and help the member and their doctor to create a detailed care plan. Dr. William Fried, Senior Medical Director of the Company's Southeast Region, stated, "We are very excited to partner with CVS Caremark and Dovetail Health on this program. By providing a personalized approach to health care we can help our members stay on track with their medications, educate them about their treatment, and prevent a repeated trip to the hospital." The Full Research Report on Aetna Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cbe9_AET]

--

Illumina Inc. Research Report

On August 19, 2013, Illumina Inc. (Illumina) announced the launch of the new reagent kits for the MiSeq benchtop sequencer. According to the Company, the new MiSeq reagents enable up to 15 gigabases (Gb) output, increased number of sequencing reads up to 25 million and overall read length up to 2x300 base pairs. The Company further stated that the innovative features of the MiSeq kits would enable researchers to perform new applications including exome sequencing on the MiSeq. Christian Henry, Senior Vice President and General Manager of Illumina's Genomic Solutions business, said, "The new MiSeq kits are another example of how we are focused on continually improving the performance and value of our sequencing platforms for our customers. The latest MiSeq system enhancements deliver the highest data quality and will open up new applications for researchers in markets as diverse as cancer, genetic disease, microbiology, agriculture and forensics." The Full Research Report on Illumina Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3cf2_ILMN]

--

Pharmacyclics Inc. Research Report

On August 22, 2013, Pharmacyclics Inc. (Pharmacyclics) announced the publication of a study that investigated ibrutinib's anti-tumor effect in patients with mantle cell lymphoma (MCL) in a popular journal, Blood. As per the study, Pharmacyclics' Vice President, Betty Chang, and colleagues, are of the opinion that the lymphocytes which increase in the peripheral blood during ibrutinib treatment are MCL cells rather than normal cells. The Company also stated that the study showed that ibrutinib, an experimental cancer treatment drug, may directly and potently inhibit MCL cell adhesion and migration in the residing lymph nodes or tissues. The Full Research Report on Pharmacyclics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/df74_PCYC]

--

WellCare Health Plans, Inc. Research Report  

On August 21, 2013, WellCare Health Plans, Inc. (WellCare) announced a contribution of $1 million to the Step Up For Students scholarship program, which provides scholarships to Florida based students, coming from low-income families in kindergarten through 12th grade. The Company said that the scholarships support student's enrollment in private schools or out-of-district public schools that best fit their needs. The Company's contribution is likely to provide scholarship support to c.198 during the 2013-2014 school year. Alec Cunningham, WellCare's CEO, said, "WellCare is committed to helping our members lead better and healthier lives, and to supporting the communities in which they live. It is an honor to be part of the Step Up for Students program, and we look forward to continuing our efforts to build brighter futures for children across Florida." The Full Research Report on WellCare Health Plans, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/be48_WCG]

--

BioCryst Pharmaceuticals Inc. Research Report

On August 8, 2013, BioCryst Pharmaceuticals Inc. (BioCryst) reported its Q2 2013 financial results. The Company's total revenue declined 80.5% YoY to $821,000 during the quarter. Net loss was $12.2 million or $0.23 per diluted share, in Q2 2013, compared to net loss of $12.3 million or $0.25 per diluted share, in Q2 2012. Additionally, Jon P. Stonehouse, President and CEO of BioCryst, provided an update on the BCX4161 Phase 1 trial and said, "The fact that we met all of our goals for the BCX4161 Phase 1 trial and secured government funding for the peramivir NDA filing represents a significant step forward for BioCryst. We look forward to initiating the BCX4161 Phase 2a clinical trial and to submitting a peramivir NDA by year end. Our very successful recent financing has allowed us to attract additional high quality investors into the company and has provided us the cash runway to carry us into 2015." The Full Research Report on BioCryst Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/f9b1_BCRX]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner